Piramal Pharma
Piramal Pharma Performance
Day Range
- Low 124.20
- High 128.20
52 Week Range
- Low 61.62
- High 142.38
- Open Price126.45
- Previous Close126.60
- Volume7239820
Start SIP in Piramal Pharma
Start SIPPiramal Pharma Investment Rating
-
Master Rating:
-
Piramal Pharma has an operating revenue of Rs. 7,539.78 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of -2% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 50%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 39% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 15% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 73 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 994 | 846 | 1,055 | 813 | 829 | 746 | 1,127 |
Operating Expenses Qtr Cr | 908 | 830 | 965 | 786 | 782 | 813 | 945 |
Operating Profit Qtr Cr | 86 | 17 | 90 | 27 | 47 | -66 | 182 |
Depreciation Qtr Cr | 51 | 50 | 53 | 47 | 47 | 45 | 51 |
Interest Qtr Cr | 28 | 34 | 34 | 33 | 29 | 20 | 20 |
Tax Qtr Cr | 19 | -8 | 24 | 3 | 35 | -7 | 35 |
Net Profit Qtr Cr | 77 | -33 | 42 | -2 | 47 | -17 | 151 |
Piramal Pharma Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹118.15
- 50 Day
- ₹110.29
- 100 Day
- ₹104.48
- 200 Day
- ₹102.99
- 20 Day
- ₹118.75
- 50 Day
- ₹106.52
- 100 Day
- ₹103.42
- 200 Day
- ₹90.40
Piramal Pharma Resistance and Support
Resistance | |
---|---|
First Resistance | 128.20 |
Second Resistance | 130.20 |
Third Resistance | 132.20 |
RSI | 71.54 |
MFI | 83.34 |
MACD Single Line | 5.29 |
MACD | 5.54 |
Support | |
---|---|
First Resistance | 124.20 |
Second Resistance | 122.20 |
Third Resistance | 120.20 |
Piramal Pharma Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 7,631,577 | 409,892,001 | 53.71 |
Week | 7,197,392 | 323,018,964 | 44.88 |
1 Month | 11,225,621 | 455,198,932 | 40.55 |
6 Month | 8,567,232 | 391,608,195 | 45.71 |
Piramal Pharma Result Highlights
Piramal Pharma Synopsis
NSE-Medical-Diversified
Piramal Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 3443.22 Cr. and Equity Capital is Rs. 1193.32 Cr. for the Year ended 31/03/2023. Piramal Pharma Ltd. is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592.Market Cap | 16,697 |
Sales | 3,709 |
Shares in Float | 86.00 |
No of funds | 182 |
Yield |
Book Value | 2.92 |
U/D Vol ratio | 2.6 |
LTDebt / Equity | 11 |
Alpha | -0.03 |
Beta | 1.69 |
Piramal Pharma
Owner Name | Sep-23 | Aug-23 | Jun-23 | Mar-23 |
---|---|---|---|---|
Promoters | 35.02% | 35.02% | 34.79% | 34.79% |
Mutual Funds | 3.8% | 3.62% | 0.91% | 0.53% |
Insurance Companies | 3.8% | 3.82% | 4.21% | 4.18% |
Foreign Portfolio Investors | 14.33% | 14.18% | 15.01% | 19.28% |
Financial Institutions/ Banks | ||||
Individual Investors | 16.95% | 16.81% | 16.77% | 13.94% |
Others | 26.1% | 26.55% | 28.31% | 27.28% |
Piramal Pharma Management
Name | Designation |
---|---|
Mrs. Nandini Piramal | Chairperson |
Mr. Peter DeYoung | Executive Director |
Mr. Vivek Valsaraj | Executive Director & CFO |
Mr. Neeraj Bharadwaj | Non Executive Director |
Mr. Nathalie Leitch | Non Executive Director |
Mr. S Ramadorai | Independent Director |
Mr. Jairaj Purandare | Independent Director |
Mr. Peter Stevenson | Independent Director |
Mr. Sridhar Gorthi | Independent Director |
Ms. Vibha Paul Rishi | Independent Director |
Piramal Pharma Forecast
Price Estimates
Piramal Pharma Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-10-27 | Quarterly Results | |
2023-08-03 | Quarterly Results | |
2023-05-24 | Audited Results | |
2023-02-08 | Quarterly Results & Rights issue | |
2022-11-08 | Quarterly Results |
Piramal Pharma FAQs
What is Share Price of Piramal Pharma ?
Piramal Pharma share price is ₹126 As on 03 December, 2023 | 05:57
What is the Market Cap of Piramal Pharma ?
The Market Cap of Piramal Pharma is ₹16696.6 Cr As on 03 December, 2023 | 05:57
What is the P/E ratio of Piramal Pharma ?
The P/E ratio of Piramal Pharma is -124.9 As on 03 December, 2023 | 05:57
What is the PB ratio of Piramal Pharma ?
The PB ratio of Piramal Pharma is 2.5 As on 03 December, 2023 | 05:57